The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

MEK and the inhibitors: from bench to bedside

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process

(2012) M. Rahmani et al.   BLOOD

BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions

(2012) Victoria Del Gaizo Moore et al.   CANCER LETTERS

Dual Inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K Inhibition-Induced Apoptosis in Human Myeloid Leukemia Cells through a GSK3- and Bim-Dependent Mechanism

(2012) M. Rahmani et al.   CANCER RESEARCH

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

(2012) Antonella De Luca et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies

(2012) Maria Rosaria Ricciardi et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation

(2012) S. Laquerre et al.   MOLECULAR CANCER THERAPEUTICS

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

(2012) G. Hatzivassiliou et al.   MOLECULAR CANCER THERAPEUTICS

BCL2A1a Over-Expression in Murine Hematopoietic Stem and Progenitor Cells Decreases Apoptosis and Results in Hematopoietic Transformation

(2012) Jean-Yves Métais et al.   PLoS One

The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy

(2011) P N Kelly et al.   CELL DEATH AND DIFFERENTIATION

Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212

(2011) J. Jing et al.   MOLECULAR CANCER THERAPEUTICS

Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim

(2010) W. Zhang et al.   CANCER RESEARCH

Anti-leukemic activity of Dasatinib in both p53wild-type and p53mutated B malignant cells

(2010) Raffaella Bosco et al.   INVESTIGATIONAL NEW DRUGS

BI-97C1, an Optically Pure Apogossypol Derivative as Pan-Active Inhibitor of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins

(2010) Jun Wei et al.   JOURNAL OF MEDICINAL CHEMISTRY

Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age?

(2010) Jean-Pierre Bourquin et al.   Expert Review of Hematology

Bcl-2 Antisense Oligonucleotide Inhibits the Proliferation of Childhood Leukemia/lymphoma Cells of the B-cell Lineage

(2009) István Szegedi et al.   PATHOLOGY & ONCOLOGY RESEARCH

Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia

(2008) M. Case et al.   CANCER RESEARCH

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis

(2008) Karina J Baum et al.   Journal of Hematology & Oncology

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

(2007) Richard Lock et al.   PEDIATRIC BLOOD & CANCER